Berger Montague Investigates Potential Securities Class Action Against Hims & Hers Health, Inc.

Core Viewpoint - Hims & Hers Health, Inc. is under investigation for potential securities claims following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and regulatory compliance issues [1][3][4] Company Overview - Hims & Hers is a telehealth company based in San Francisco, California, providing prescription treatments for various health issues, including weight loss, sexual health, mental health, and dermatology [2] - The company has recently entered the GLP-1 medication market, which includes drugs for obesity and type 2 diabetes, specifically semaglutide, the active ingredient in Novo Nordisk's Wegovy® and Ozempic® [2] Recent Developments - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers, citing deceptive marketing practices and the sale of unapproved compounded versions of semaglutide [3] - Following this announcement, Hims & Hers shares fell by over 26% during intraday trading, indicating significant investor concern regarding the company's regulatory compliance and reputational risks [3] Investigation Details - Berger Montague is investigating whether Hims & Hers and its officers made materially false or misleading statements or omitted important information about the regulatory status of its GLP-1 offerings and the risks associated with its partnership with Novo Nordisk [4]